Marvel BiosciencesMBCOF 34 EV-to-EBIT is -9.95 as of Jul. 11, 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 366 Biotechnology companies, Marvel Biosciences ranks worse than 273223.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Marvel Biosciences's Enterprise Value for the quarter that ended in Apr. 2026 was $8.68 Mil.
Marvel Biosciences's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marvel Biosciences EV-to-EBIT Related Terms
Marvel Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Marvel Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Marvel Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marvel Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marvel Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Marvel Biosciences's EV-to-EBIT falls into.
Marvel Biosciences's current Enterprise Value is $7.78 Mil.
Marvel Biosciences's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marvel Biosciences (MBCOF) has a EV-to-EBIT of -9.95 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Marvel Biosciences and its competitors. According to the industry distribution chart, Marvel Biosciences ranks #999999 out of 366 companies in the Biotechnology industry.
Is Marvel Biosciences' EV-to-EBIT too high?
Marvel Biosciences' current EV-to-EBIT is -9.95. Based on the distribution chart, Marvel Biosciences ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #999999 out of 366 companies for EV-to-EBIT. This places Marvel Biosciences in the lower half of its industry. The industry median EV-to-EBIT is 15.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.02, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Marvel Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current EV-to-EBIT is -9.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current EV-to-EBIT of -9.95. The current EV-to-EBIT is -9.95. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current EV-to-EBIT is -9.95 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score
Get the complete analysis for MBCOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBCOF has been successfully added to your 
